Video

VIDEO: High TILs associated with less efficacy from trastuzumab


 

AT SABCS 2014

References

SAN ANTONIO – Know your patient’s number: Dr. Edith A. Perez of the Mayo Clinic in Jacksonville, Fla., explains in a video interview how the level of stromal tumor infiltrating lymphocytes (TILs) in women with early-stage, HER2+ breast cancer may be useful in identifying a subset who might potentially do quite well with chemotherapy alone.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

bjancin@frontlinemedcom.com

Recommended Reading

ROR score aids prognosis after 5 years on tamoxifen
MDedge ObGyn
Meditation, yoga earn high marks as supportive care during breast cancer treatment
MDedge ObGyn
VIDEO: An easy way to improve breast biopsy practices
MDedge ObGyn
Mastectomies, reconstruction, on the rise for women with early stage disease
MDedge ObGyn
Breast cancer relapse risk halved since 1986
MDedge ObGyn
Too many elderly with breast cancer still receive radiotherapy
MDedge ObGyn
Ultrasound screening for dense breasts is high cost, offers little benefit
MDedge ObGyn
Pictilisib plus fulvestrant boosts PFS in ER/PR+ patients
MDedge ObGyn
VIDEO: Is there a future for pictilisib in the treatment of HR+ breast cancer?
MDedge ObGyn
Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients
MDedge ObGyn